Soliton, a medical device company with a novel and proprietary rapid pulse acoustic shockwave technology licensed from The University of Texas, has brought on supervising physicians Omer Ibrahim, MD, FAAD, and Carolyn I. Jacob, MD, FAAD, as well as a third study site for its upcoming expanded pivotal Cellulite Clinical Trial. The site, Chicago Cosmetic Surgery and Dermatology, joins two previously identified sites in what is anticipated to be a four-site trial.
The expanded Cellulite Clinical Trial builds upon a proof-of-concept trial conducted earlier this year using the company’s Rapid Acoustic Pulse (RAP) device to reduce cellulite. Up to 75 subjects will be treated at Chicago Cosmetic Surgery and Dermatology, Capital Laser in Chevy Chase, Maryland, SkinCare Physicians in Boston and at one yet-to-be-identified site.
